Jupiter Neurosciences has developed the first and only resveratrol product that safely reaches therapeutic levels without GI-side effects creating treatment possibilities in many indications.
Our platform product JOTROL™ is being studied as an oral medication for Alzheimer’s disease and for people with rare diseases.
PIPELINE Development Strategy: One Phase I study enabling 3 rare diseases and MCI starting directly in Phase II
Results from the Phase I pharmacokinetics study will be cross-referenced for all future JOTROL™ indications. This will enable trials to proceed
directly to Phase II.
